In a report published Wednesday, Hilliard Lyons reiterated its Underperform rating on HCP (NYSE: HCP ). HIlliard Lyons noted, “Following the conference call and a more in-depth look at HCP's results, we are fine-tuning our 2013 FFO estimate slightly to $3.03 a share, which is slightly above guidance. We are